Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21281650 | 0.88 | ALDH1A1 (0.39) | NPC1ALDH1A1MEN1KMT2ARXFP1 | |
| SCHEMBL20156082 | 0.85 | ITGB3 (0.49) | — | |
| SCHEMBL21281684 | 0.83 | SUCNR1 (0.37) | NPC1THRBL3MBTL1MAPK1SUCNR1 | |
| SCHEMBL21281666 | 0.80 | SUCNR1 (0.39) | SUCNR1 | |
| SCHEMBL21272322 | 0.77 | ITGB3 (0.57) | — | |
| SCHEMBL29857150 | 0.77 | ITGB3 (0.57) | — | |
| SCHEMBL21272323 | 0.77 | ITGB3 (0.57) | — | |
| SCHEMBL23912908 | 0.77 | NPC1 (0.34) | NPC1ALDH1A1MEN1KMT2ARXFP1 | |
| SCHEMBL21281625 | 0.77 | ITGB3 (0.40) | NPC1ALDH1A1MEN1KMT2ARXFP1 | |
| SCHEMBL20156299 | 0.76 | ADORA3 (0.37) | NPC1KDM4EPOLBLMNASUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | NPC1 2104/4885ALDH1A1 779/4885MEN1 642/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | NPC1 2104/4885ALDH1A1 779/4885MEN1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.